Lineage Cell Therapeutics

Lineage Cell Therapeutics Gross Margin

The Gross Margin of Lineage Cell Therapeutics (LCTX) as of Nov 5, 2026 is 94.19 %. In the previous year, Gross Margin was 96.48 % — a change of -2.37% (lower).

Gross Margin

94.19 %

YoY

-2.37%

Last updated:

Gross Margin of Lineage Cell Therapeutics is 2025 94.19 % . Gross Margin of Lineage Cell Therapeutics was 2024 96.48 % . It decreases by -2.37% lower compared to the previous year.

Lineage Cell Therapeutics's gross margin stands at 94.2%, up from 63.4% several years earlier.

The Lineage Cell Therapeutics Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
78.67 USD
Jan 1, 2019
72.12 USD
Jan 1, 2020
50.19 USD
Jan 1, 2021
63.40 USD
Jan 1, 2022
95.05 USD
Jan 1, 2023
92.50 USD
Jan 1, 2024
96.48 USD
Jan 1, 2025
94.19 USD
The Lineage Cell Therapeutics Gross Margin history
YEARGross MarginYoY
94.19 %-2.37%
96.48 %+4.31%
92.50 %-2.68%
95.05 %+49.92%
63.40 %+26.31%
50.19 %-30.41%
72.12 %-8.32%
78.67 %-13.19%
90.63 %+7.75%
84.10 %+49.35%
56.31 %-1.19%
56.99 %+7,783.63%
0.72 %-2.76%
0.74 %-25.65%
1.00 %0.00%
1.00 %0.00%
1.00 %0.00%
1.00 %0.00%
1.00 %0.00%
1.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lineage Cell Therapeutics Stock analysis

What does Lineage Cell Therapeutics do? Lineage Cell Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of cell therapies for various diseases. Originally established in 1990 as VisiGenics Inc., specializing in proteomic and genetic analysis, the company later changed its name to Lineage Cell Therapeutics Inc. to reflect its focus on the research and development of stem cell therapies. Lineage Cell Therapeutics develops and markets cell therapy products based on its own patents and discoveries, including therapies for eye, neurodegenerative, and cancer diseases. The company's proprietary technology platform gives it a crucial position in the field of cell therapy. Additionally, Lineage Cell Therapeutics collaborates with academic institutions and other biopharmaceutical companies to expedite the process of commercializing cell therapies. The company offers a wide range of cell therapies for various injuries and diseases, with key applications including: - OPC1: A cell-based therapy for spinal cord injuries caused by damage to the spinal cord. This therapy is being developed on the astrocyte differentiation treatment platform derived from embryonic stem cells (ES cells). - OpRegen: A cell-based regenerative product for dry age-related macular degeneration (tAMD). This therapy is based on the retinal pigment epithelium cell differentiation treatment platform derived from human embryonic stem cells. - VAC: An immunotherapy for cancer treatment. This treatment involves dendritic cells isolated from the patient's blood and genetically modified to present cancer-specific antigens. The goal is to stimulate the patient's immune system to trigger a specific immune response against cancer. Lineage Cell Therapeutics also pursues a strong expansion strategy. In 2020, it acquired a majority stake in AgeX Therapeutics, a biotechnology company focused on developing innovations in the field of stem cells. This acquisition strengthened the company's capacity for innovation and increased its ability to capitalize on future growth opportunities through partnerships, licensing, and product launches. Overall, Lineage Cell Therapeutics has become a significant player in the field of cell therapy, thanks to the use of cutting-edge technology and years of experience in the life science industry. One of the company's main goals is to develop and manufacture groundbreaking cell therapies to ultimately improve the lives of patients worldwide. Lineage Cell Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lineage Cell Therapeutics stock

Gross Margin of Lineage Cell Therapeutics is 94.19 % in 2025.

Gross Margin of Lineage Cell Therapeutics changed from 96.48 % to 94.19 %, representing a -2.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Lineage Cell Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Lineage Cell Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Lineage Cell Therapeutics

All Key Metrics — Lineage Cell Therapeutics